Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Several Oxford Cancer researchers present at the American Association for Cancer Research (AACR) Annual Meeting.

The AACR Annual Meeting is one of the largest events in the cancer conference calendar and draws global audiences of scientists, clinicians, other health care professionals, survivors, patients, and advocates.

Oxford’s cancer research is represented by twelve presenters at this year’s meeting.


  • Dr Andrew Erickson (Nuffield Department of Surgical Sciences) presents “The spatial landscape of clonal somatic mutations in benign and malignant tissue” in the session on Cancer Genomics and Biology (Mini symposium).
  • Dr Véronique Lafleur (Ludwig Institute for Cancer Research and Target Discovery Institute) presents “Bi-directional crosstalk between the HIF and AHR transcription factors in clear cell kidney cancer” in the session on Transcription Factors in Cancer (Mini symposium)
  • Dr Eileen Parkes (Department of Oncology) presents “STING mediated inflammatory signaling in BRCA-mutant breast cancer” in the session on Triple Negative Breast Cancer (Advances in organ site research).
  • Professor Yang Shi (Ludwig Institute for Cancer Research) presents “Epigenetic regulation in immuno-oncology” in the session on Epigenetics, Chromatin Architecture, and Gene Regulation: Mechanisms and Therapeutic Opportunities in Cancer (Major symposium)


  • Dr Thomas Carroll (Ludwig Institute for Cancer Research): “Comprehensive molecular profiling to predict first-line immunochemotherapy outcomes in inoperable esophageal adenocarcinoma”
  • Jessica Kindrick (Ludwig Institute for Cancer Research and Target Discovery Institute): “Correlating locus-specific changes in histone trimethylation and gene expression in hypoxia”
  • Samvid Kurlekar (Ludwig Institute for Cancer Research and Target Discovery Institute): “Negative cellular outcomes following acute in vivo Vhl inactivation in mice”
  • Dr Joanna Lima (Ludwig Institute for Cancer Research and Target Discovery Institute): “A novel lineage-tracing model of Vhl deletion reveals time-dependent cellular changes in the kidney”
  • Dr Olivia Lombardi (Ludwig Institute for Cancer Research and Target Discovery Institute): “Multi region single cell sequencing reveals dedifferentiation programs, angiogenic heterogeneity and the effect of microenvironmental hypoxia in ccRCC tumors”
  • Professor David Mole (Ludwig Institute for Cancer Research and Target Discovery Institute): “Pan-cancer analysis of HIF pathways defines a robust molecular signature that reflects tissue and cellular hypoxia in bulk and single-cell RNA-seq analyses”
  • Dr Wayne Paes (Nuffield Department of Medicine): “First-in-class inhibitors of ERAP1 alter the HLA-I-restricted cancer immunopeptidome leading to the generation of novel peptides presented for immune recognition”
  • Chee Kin Then (Department of Oncology): “Can the gut microbiota both radiosensitize tumors and spare normal tissue toxicity?”